Veru Announces Oct. 6 Date For FDA Advisory Committee Meeting To Review Emergency Use Authorization For Sabizabulin For Hospitalized COVID-19 Patients At High Risk For Acute Respiratory Distress Syndrome
MIAMI, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast
Perma-Pipe Inlt Hldgs Q2 EPS $0.23 Down From $0.41 YoY, Sales $37.00M Down From $39.80M YoY
Perma-Pipe Inlt Hldgs (NASDAQ:PPIH) reported quarterly earnings of $0.23 per share. This is a 43.9 percent decrease over earnings of $0.41 per share from the same period last year. The company reported $37.00 million in
Bristow Awarded Multi-Year Equinor Search And Rescue Contract
Equinor awarded Bristow Norway a search and rescue contract starting September 1, 2023. The initial contract is for four years and includes three one-year options for a potential total of seven
SiriusPoint Announces Scott Egan As Chief Executive Officer
SiriusPoint Ltd. ("SiriusPoint" or the "Company") (NYSE:SPNT), a global specialty insurer and reinsurer, has announced that Scott Egan has been appointed as the Company's Chief Executive
COMSovereign Announces Departure Of CEO Dan Hodges, Appoints David Knight Interim CEO
DALLAS, Sept. 7, 2022 /PRNewswire/ -- COMSovereign Holding Corp. (NASDAQ:COMS) ("COMSovereign" or the "Company"), a U.S.-based developer of 4G LTE Advanced and 5G Communication Systems and
Academy Sports Q2 EPS $2.30 Beats $2.08 Estimate, Sales $1.69B Miss $1.71B Estimate
Academy Sports (NASDAQ:ASO) reported quarterly earnings of $2.30 per share which beat the analyst consensus estimate of $2.08 by 10.58 percent. This is a 1.71 percent decrease over earnings of $2.34 per share from the
Praxis Precision Medicines Announces Plan To Start PRAX-222 EMBRAVE Clinical Study
BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central